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Results  
The recordings showed that the planner generally works 
iteratively on lowering OAR dose and increasing target 
dose. This process visualizes as a zig-zag pattern in the 
bi-objective problem formulation where both objectives 
are eventually improved (Fig.1a). In the bi-objective 
problem formulation, all clinical plans were inferior to 
the Pareto front plans obtained with the MOEA (Fig.1b). 
In the observer study, in all cases the observers chose a 
plan from the Pareto front as the best plan, and 
appreciated to directly see the trade-offs for that 
particular patient (Fig.1b). The clinical plan was in 4/20 
cases considered to be the worst plan. The observers 
agreed on the best plan for 2 patients, which was the 
plan with the highest possible coverage while still 
satisfying all OAR criteria.  
 
 
 
Conclusion  
Our novel bi-objective brachytherapy planning method is 
parameterless and directly optimizes treatment plans on 
the evaluation criteria of a clinical protocol. It results in 
a set of high-quality plans to intuitively select from. In all 
cases, such a plan was preferred over the clinical plan. 
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Purpose or Objective  
To develop a novel high resolution experimental method 
for validating Monte Carlo-derived TG-43 brachytherapy 
source data, and model-based treatment planning 
systems. Experimental verification is recommended in 
the “Report of the High Energy Brachytherapy Source 
Dosimetry (HEBD) Working Group, 2012”, however, the 
steep dose gradients with a wide dynamic dose range and 
rapid change in dose rate has been a limitation for the 
ability of common detectors to obtain accurate 
measurements. In this study, we tested a micro silica 
bead TLDs recently developed at University of Surrey for 
suitability to perform accurate dose measurements 
around 60Co and 192Ir clinical HDR brachytherapy sources. 
The micro silica beads proven dosimetric characteristics 
(independency from dose rate and angle of radiation 
incidence) accompanied by small ‘donut shape’ physical 
dimensions (1.2 mm diameter and 0.9 mm thickness (Fig. 
1 (a)) along with chemically inert nature, ease of use and 
reusability were considered as a very promising detectors 
for this application. 
Material and Methods  
Novel dosimeter positioning templates were designed and 
produced using AutoCAD software. The micro silica bead 
TLDs were threaded using cotton yarns and stitched onto 
the template to accurately position the dosimeters within 
± 0.1 mm, in a full-scatter water tank (Fig 1(b) and 1(c)).  
Measurement setup for radial dose distribution and dose 
linearity is shown on (Fig 1(c)) and (Fig 1(b)). The used 
dose rates were form 10 to 4000 cGy/min and dose 
ranged from 0.5 to 40 Gy. The results of dose distribution 
measurements around the sources were compared to TG-
43 tabulated data and simultaneously irradiated EBT3 
Gafchromic film. A TOLADO TL system was employed for 
read out of the TLDs. Triple-channel dosimetry using 
FilmQAPro with uncertainty reduction technique was used 
for film dosimetry  
 
 
Results  
The novel experimental method suitably addressed the 
dosimetry challenges. A linear dose response was 
observed in the investigated range, 0.5–40 Gy, with a 
correlation coefficient of R2 > 0.999. The ability of 
detector to assess the high gradient dose distribution 
with variable dose rate within the range of 10–4000 
cGy/min around the sources was compared to the TG-43 
data to that of EBT3 film and found to be within 
experimental uncertainty (Fig 2 (a) and (b)). 
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Conclusion  
A novel, high spatial resolution experimental method was 
developed for validating brachytherapy dosimetry using 
micro silica bead TLDs on high precision templates. The 
measured radial dose distributions around both of the 
60Co and 192Ir sources were comparable within the 
experimental uncertainty to the relevant TG-43 data and 
superior to that of EBT3 Gafchromic film measurement in 
terms of the dynamic dose range evaluated. The 
experimental method presented is suitable to address the 
challenge of HDR brachytherapy dosimetry. 
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Purpose or Objective  
Brachytherapy uses sealed radioactive sources into the 
tumor to deliver the radiation dose. Due to the high dose 
per fraction and strong gradients in High dose rate 
brachytherapy (HDR-BT), consequences on dose delivery 
may be significant if errors occur in the treatment 
workflow. 
Therefore, in order to verify and ensure that the dose is 
correctly delivered, periodic quality controls (QC) are 
carried out on machines according to the 
recommendations of the ESTRO BOOKLET 8 (1). Many 
tools, complex to use, are required. We therefore 
developed an integrated quality assurance (QA) tool to 
check the mandatory machine parameters as well as the 
dose delivered. Within this project, Gallium Nitride (GaN) 
dosimeters (2) were studied. 
Material and Methods  
First, dosilab Company has designed a phantom based on 
four GaN dosimeters with different inserts for machine 
QA: 1 and 2 channels. Specific calculation methods based 
on GaN dosimeter responses are used to accurate 
determination of dwell times and dwell position (Fig. 1).  
 
 
For this study, we validated the software development 
and check the accuracy on the source dwell position and 
on the measured dose (ESTRO guidelines 2mm and 5% 
respectively). Ten measurements were acquired for a 
prescribe dose of 5Gy and by using different inserts. Then 
we introduced an error on the source dwell positions 
from 1 to 10 mm to test the robustness of the system on 
the measured dose. Finally, we developed a 6-channel 
insert (Fig. 1) to perform quantitative patient quality 
control measurements in comparison with treatment 
plans.  
So, measurements of repeatability and reproducibility 
have been carried out on HDR-BT phantom. 
Results  
After ten successive measurements, errors between the 
measured and planned source dwell positions are not 
significant and respect the ESTRO guidelines of 2mm 
(mean values of 0.21mm [range -0.47:0.45], 0.14mm 
[range -0.53;0.38] and 0.06mm [range -0.59;0.33] for 
inserts with 1, 2 and 6-channels respectively). Taking into 
account the dose delivered, mean differences between 
measured and planned dose are 0.24% [range -3.24; 
2.69], -1.64% [range -7.42;1.47] and -1.2% [range -
2.93;2.72] for inserts with 1, 2 and 6-channels 
respectively. Results respect the ESTRO guidelines of 5%.
  
Finally, if we consider the error detection threshold with 
the GaN phantom, we notice that a dose greater than 5% 
is visible with an error of 2mm for insert 1 channel and 
3mm for inserts 2 and 6-channels (Fig. 2). 
 
 
 
 
 
